PDS Biotech Chief Medical Officer Dr. Lauren V. Wood to Address 2022 International Head and Neck Conference
25 oct. 2022 08h00 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Oct. 25, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
PDS Biotech to Present at the LD Micro Main Event XV
19 oct. 2022 08h00 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
PDS Biotech Announces Abstract Demonstrating Versatility of the Versamune® Platform in Oncology Accepted for Presentation at AACR Special Conference on Tumor Immunology and Immunotherapy
17 oct. 2022 08h00 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Oct. 17, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
PDS Biotech to Host Head and Neck Cancer KOL Roundtable on October 26, 2022
12 oct. 2022 08h00 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Oct. 12, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
PDS Biotech Announces Expanded Interim Data in PDS0101 Triple Combination Phase 2 Trial Targeting Advanced HPV-Positive Cancers
11 oct. 2022 08h00 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Oct. 11, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
PDS Biotech Reports An Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
07 oct. 2022 16h01 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Oct. 07, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
PDS Biotech Announces Abstracts Involving Research of PDS0101 Accepted for Presentation at SITC 2022
05 oct. 2022 08h00 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Oct. 05, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
PDS Biotech Announces Successful End-of-Phase 2 Meeting With the FDA and Preparation for the Registrational Trial of PDS0101 in Combination With KEYTRUDA®
03 oct. 2022 08h00 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Oct. 03, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
PDS Biotech Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
23 sept. 2022 16h05 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Sept. 23, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
PDS Biotech to Participate at Cantor Fitzgerald’s Oncology & HemOnc Conference
22 sept. 2022 08h00 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Sept. 22, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...